- Home
- MTRX vs BMEA Comparison
MTRX vs BMEA Comparison
Compare MTRX & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTRX
- BMEA
- Stock Information
- Founded
- MTRX 1984
- BMEA 2017
- Country
- MTRX United States
- BMEA United States
- Employees
- MTRX N/A
- BMEA N/A
- Industry
- MTRX Engineering & Construction
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- MTRX Consumer Discretionary
- BMEA Health Care
- Exchange
- MTRX Nasdaq
- BMEA Nasdaq
- Market Cap
- MTRX 373.0M
- BMEA 65.8M
- IPO Year
- MTRX 1990
- BMEA 2021
- Fundamental
- Price
- MTRX $13.35
- BMEA $1.93
- Analyst Decision
- MTRX Strong Buy
- BMEA Strong Buy
- Analyst Count
- MTRX 1
- BMEA 10
- Target Price
- MTRX $20.00
- BMEA $22.30
- AVG Volume (30 Days)
- MTRX 174.5K
- BMEA 2.3M
- Earning Date
- MTRX 09-08-2025
- BMEA 07-30-2025
- Dividend Yield
- MTRX N/A
- BMEA N/A
- EPS Growth
- MTRX N/A
- BMEA N/A
- EPS
- MTRX N/A
- BMEA N/A
- Revenue
- MTRX $742,408,000.00
- BMEA N/A
- Revenue This Year
- MTRX $9.98
- BMEA N/A
- Revenue Next Year
- MTRX $20.42
- BMEA N/A
- P/E Ratio
- MTRX N/A
- BMEA N/A
- Revenue Growth
- MTRX N/A
- BMEA N/A
- 52 Week Low
- MTRX $8.65
- BMEA $1.29
- 52 Week High
- MTRX $15.75
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- MTRX 62.53
- BMEA 50.04
- Support Level
- MTRX $13.31
- BMEA $1.58
- Resistance Level
- MTRX $13.84
- BMEA $2.03
- Average True Range (ATR)
- MTRX 0.38
- BMEA 0.15
- MACD
- MTRX 0.01
- BMEA -0.00
- Stochastic Oscillator
- MTRX 76.16
- BMEA 80.00
About MTRX Matrix Service Company
Matrix Service Co is an engineering and construction provider for large industrial projects, primarily in the oil and gas, power, petrochemical, industrial, mining, and minerals markets. It offers engineering, fabrication, construction, and maintenance services, operating across three segments namely Utility and Power Infrastructure; Process and Industrial Facilities; and Storage and Terminal Solutions.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.